Prognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancer

Table 2 Multivariate analysis for independent predictors of biochemical failure free survival

	P value	HR	95%CI for HR
			Lower	Upper
LHRHa type	0.757	0.0	0.0	1.24E+19
D'Amico risk group (ref: intermediate)	0.397	1.5	0.6	3.89E+00
AJCC 2010 T stage (ref: T1)	0.953
T2a	0.909	2869.3	0.0	2.85E+62
T2b	0.915	1646.5	0.0	1.64E+62
T2c	0.912	2150.3	0.0	2.14E+62
T3a	0.91	2583.9	0.0	2.57E+62
T3b	0.908	3108.0	0.0	3.10E+62
Gleason score (ref: ≤ 6)	0.799
7	0.932	1.0	0.5	1.99E+00
≥ 8	0.564	1.3	0.6	2.71E+00

LHRHa: Luteinizing Hormone-Releasing Hormone analog; AJCC: American Joint Committee on Cancer; T: Tumor.